Do you want to change careers? Are you absolutely sure?
From my own career change to the stories I hear from my clients and workshop students, often we think we want to change careers when the problem is our work environment instead. If you find yourself stuck, unsure what to do next, or t
Investors looking for profits in the healthcare sector had a difficult time in 2017 if they weren’t in biotech. The Health Care SPDR ETF (NYSE: XLV) only gained 13.15% last year, while the S&P 500 climbed 22.5% over the same time period.
But the biotech sector crushed the market, with the SPDR S&P Biotech ETF (NYSE: XBI) returning a market-beating 43.36% in 2017, nearly....More>>>
After five years of strong growth in apparel and footwear, Nike’s (NYSE: NKE) shareholders were rewarded with returns in excess of 100%. These returns greatly outpaced the 80% return delivered by the S&P 500 (NYSEARCA:VOO) over the same time frame. Unfortunately, 2016 was a tough year for Nike’s shareholders. Holders of Nike’s stock witnessed the stock price tumble over 15%....More>>>
Biotech stocks have climbed steadily higher over the past few weeks. Still, the iShares Nasdaq Biotechnology ETF (IBB) has remained range bound between $240 and $290 for much of 2016.
So with major stock indices hitting new record highs, can biotech stocks break free? Perhaps, says Michael Yee, the industry analyst for RBC Capital Markets. But first, the market wants the political rhetoric....More>>>
It’s been a long time since Valeant Pharmaceuticals (NYSE:VRX) stock was in a legitimate uptrend. Despite the hiring of a new CEO last year to right the ship, Valeant’s share price has continued to fall.
The question that investors must ask now isn’t when Valeant will turn things around. Instead, the key question is whether it will happen at all. Can Valeant Pharmaceuticals....More>>>
Wall Street on Monday didn’t just cash in on one winner, or a daily double, or even a trifecta. It notched astock market-style superfecta, with all four major U.S. stock indexes — representing blue chip names, technology stocks, small caps and large-company stocks — all closing at record highs on the same day for the first time in 17years.
I made an invidious buy recommendation for Adobe (ADBE) last June 2016. Unlike the go-short recommendation of Investor Wand last month, I am again endorsing going long on ADBE. Adobe's phenomenal performance in the stock market is largely thanks to its continuing monopoly on commercial design/cre
As earnings season starts to taper off, there are some stragglers in tech still reporting earnings. Design software company Autodesk (NASDAQ:ADSK) was one notable company to report quarterly results last week.
But another must-see story this week came from outside of earnings-season newsw
The average stock in the Nasdaq 100 is up just over 3% year to date. Using snapshots from our popular Trend Analyzer tool, below is a look at the best and worst performing stocks in the Nasdaq 100 so far in 2018.
At the top of the list is Netflix (NASDAQ:NFLX) with a year-to-date gain of
There aren't a lot of tech companies that one can imagine Warren Buffett and the rest of Berkshire Hathaway's (BRK.A) investment team taking a close look at, given their investment philosophy. But exceptions do exist.
The reasons behind Buffett's historical aversion to investing in tech a